HK1086835A1 - N-[({'4-substituted piperazine-1-y}sulfonylmethyl)alkyl]-n-hxdroxyformamide compounds as metallopro teinase inhibitors - Google Patents
N-[({'4-substituted piperazine-1-y}sulfonylmethyl)alkyl]-n-hxdroxyformamide compounds as metallopro teinase inhibitorsInfo
- Publication number
- HK1086835A1 HK1086835A1 HK06106939A HK06106939A HK1086835A1 HK 1086835 A1 HK1086835 A1 HK 1086835A1 HK 06106939 A HK06106939 A HK 06106939A HK 06106939 A HK06106939 A HK 06106939A HK 1086835 A1 HK1086835 A1 HK 1086835A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hxdroxyformamide
- metallopro
- sulfonylmethyl
- alkyl
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0301922A SE0301922D0 (sv) | 2003-06-27 | 2003-06-27 | Novel compounds |
| PCT/GB2004/002702 WO2005000822A1 (en) | 2003-06-27 | 2004-06-23 | N-{‘4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1086835A1 true HK1086835A1 (en) | 2006-09-29 |
Family
ID=27656653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK06106939A HK1086835A1 (en) | 2003-06-27 | 2006-06-17 | N-[({'4-substituted piperazine-1-y}sulfonylmethyl)alkyl]-n-hxdroxyformamide compounds as metallopro teinase inhibitors |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US7485644B2 (xx) |
| EP (1) | EP1644340B1 (xx) |
| JP (1) | JP4701167B2 (xx) |
| KR (1) | KR20060026440A (xx) |
| CN (2) | CN102229589A (xx) |
| AR (1) | AR044931A1 (xx) |
| AT (1) | ATE414063T1 (xx) |
| AU (1) | AU2004251104B2 (xx) |
| BR (1) | BRPI0411929A (xx) |
| CA (1) | CA2529468A1 (xx) |
| CO (1) | CO5650254A2 (xx) |
| CY (1) | CY1108757T1 (xx) |
| DE (1) | DE602004017733D1 (xx) |
| DK (1) | DK1644340T3 (xx) |
| ES (1) | ES2315675T3 (xx) |
| HK (1) | HK1086835A1 (xx) |
| HR (1) | HRP20090009T3 (xx) |
| IL (1) | IL172615A0 (xx) |
| IS (1) | IS8257A (xx) |
| MX (1) | MXPA05013460A (xx) |
| MY (1) | MY138680A (xx) |
| NO (1) | NO20060444L (xx) |
| NZ (1) | NZ544208A (xx) |
| PL (1) | PL1644340T3 (xx) |
| PT (1) | PT1644340E (xx) |
| RU (1) | RU2351595C2 (xx) |
| SA (1) | SA04250224B1 (xx) |
| SE (1) | SE0301922D0 (xx) |
| SI (1) | SI1644340T1 (xx) |
| TW (1) | TW200524898A (xx) |
| UA (1) | UA81491C2 (xx) |
| UY (1) | UY28387A1 (xx) |
| WO (1) | WO2005000822A1 (xx) |
| ZA (1) | ZA200510458B (xx) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0427403D0 (en) | 2004-12-15 | 2005-01-19 | Astrazeneca Ab | Novel compounds I |
| DK1951674T3 (da) * | 2005-10-26 | 2012-01-02 | Merck Serono Sa | Sulfonamidderivater og anvendelse deraf til modulation af metalloproteinaser |
| CN101007794B (zh) * | 2006-01-26 | 2010-09-01 | 中国科学院上海药物研究所 | N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途 |
| WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| ES2592154T3 (es) * | 2010-07-08 | 2016-11-28 | Kaken Pharmaceutical Co., Ltd. | Derivado de N-hidroxiformamida y medicamento que contiene el mismo |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2317455C (en) | 1998-01-30 | 2011-01-25 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives |
| GB9919776D0 (en) * | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| JP2003501414A (ja) * | 1999-06-04 | 2003-01-14 | アストラゼネカ・アクチエボラーグ | メタロプロテイナーゼの阻害剤 |
| UA73155C2 (en) * | 2000-02-21 | 2005-06-15 | Astrazeneca Ab | Substituted by piperidine and piperazine n-hydroxyformamides as metalloproteinase inhibitors |
| GB0119472D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
| AU2003221786A1 (en) * | 2002-04-25 | 2003-11-10 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| WO2004113312A1 (en) * | 2003-06-19 | 2004-12-29 | Celltech R & D Limited | Hydroxamate sulfonamides as cd23 shedding inhibitors |
-
2003
- 2003-06-27 SE SE0301922A patent/SE0301922D0/xx unknown
-
2004
- 2004-06-23 EP EP04743053A patent/EP1644340B1/en active Active
- 2004-06-23 CA CA002529468A patent/CA2529468A1/en not_active Abandoned
- 2004-06-23 SI SI200430979T patent/SI1644340T1/sl unknown
- 2004-06-23 KR KR1020057024709A patent/KR20060026440A/ko active IP Right Grant
- 2004-06-23 RU RU2005141058/04A patent/RU2351595C2/ru not_active IP Right Cessation
- 2004-06-23 JP JP2006516467A patent/JP4701167B2/ja not_active Expired - Fee Related
- 2004-06-23 CN CN201110103041XA patent/CN102229589A/zh active Pending
- 2004-06-23 UA UAA200511723A patent/UA81491C2/uk unknown
- 2004-06-23 NZ NZ544208A patent/NZ544208A/en unknown
- 2004-06-23 DK DK04743053T patent/DK1644340T3/da active
- 2004-06-23 DE DE602004017733T patent/DE602004017733D1/de active Active
- 2004-06-23 PT PT04743053T patent/PT1644340E/pt unknown
- 2004-06-23 BR BRPI0411929-0A patent/BRPI0411929A/pt not_active IP Right Cessation
- 2004-06-23 PL PL04743053T patent/PL1644340T3/pl unknown
- 2004-06-23 AU AU2004251104A patent/AU2004251104B2/en not_active Ceased
- 2004-06-23 CN CN2004800182447A patent/CN1812974B/zh not_active Expired - Fee Related
- 2004-06-23 WO PCT/GB2004/002702 patent/WO2005000822A1/en active Application Filing
- 2004-06-23 ES ES04743053T patent/ES2315675T3/es active Active
- 2004-06-23 MX MXPA05013460A patent/MXPA05013460A/es active IP Right Grant
- 2004-06-23 US US10/561,747 patent/US7485644B2/en not_active Expired - Fee Related
- 2004-06-23 AT AT04743053T patent/ATE414063T1/de active
- 2004-06-25 TW TW093118692A patent/TW200524898A/zh unknown
- 2004-06-25 AR ARP040102258A patent/AR044931A1/es not_active Application Discontinuation
- 2004-06-25 MY MYPI20042517A patent/MY138680A/en unknown
- 2004-06-25 UY UY28387A patent/UY28387A1/es unknown
- 2004-07-14 SA SA04250224A patent/SA04250224B1/ar unknown
-
2005
- 2005-12-15 IL IL172615A patent/IL172615A0/en unknown
- 2005-12-22 ZA ZA200510458A patent/ZA200510458B/xx unknown
- 2005-12-27 CO CO05130352A patent/CO5650254A2/es not_active Application Discontinuation
-
2006
- 2006-01-23 IS IS8257A patent/IS8257A/is unknown
- 2006-01-27 NO NO20060444A patent/NO20060444L/no not_active Application Discontinuation
- 2006-06-17 HK HK06106939A patent/HK1086835A1/xx not_active IP Right Cessation
-
2009
- 2009-01-08 HR HR20090009T patent/HRP20090009T3/xx unknown
- 2009-01-19 CY CY20091100064T patent/CY1108757T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP1967A (en) | Thiazolidinone compounds as inhibitors of Hyak3 | |
| PL372198A1 (en) | Heteroaryl compounds useful as inhibitors of gsk-3 | |
| AU2002357882A8 (en) | Small-molecule inhibitors of interleukin-2 | |
| EP1551801A4 (en) | NOVEL GAMMA-LACTAMES AS INHIBITORS OF BETA-SECRETASE | |
| EP1613595A4 (en) | NOVEL COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASE | |
| IL174375A0 (en) | Novel heterocyclic compounds as hsp90-inhibitors | |
| IL175106A0 (en) | Novel keto-oxadiazole derivatives as cathepsin inhibitors | |
| AU2002344567A1 (en) | Heterocyclic amide compounds as apolipoprotein b inhibitors | |
| HK1081186A1 (en) | Pyrazole compositions useful as inhibitors of gsk-3 | |
| IL169691A0 (en) | Malonamide derivatives as gamma-secretase inhibitors | |
| EP1756040A4 (en) | PHENYL CARBOXAMIDE COMPOUNDS FOR USE AS BETA SECRETASE INHIBITORS IN THE TREATMENT OF ALZHEIMER'S DISEASE | |
| AU2003261434A8 (en) | Iminothiazolidinones as inhibitors of hcv replication | |
| EP1485335A4 (en) | PRODUCTION OF ALKYL AROMATIC COMPOUNDS | |
| SI2039685T1 (sl) | Heterobiciklične spojine kot P38 inhibitorji | |
| IL173930A0 (en) | Pharmaceutical compositions containing forms of r-baclofen | |
| EP1624844A4 (en) | FORMULATION BASED ON MORINDA CITRIFOLIA FOR THE INHIBITION OF METASTASES OF CARCINOGENIC CELLS | |
| IL185035A0 (en) | Derivatives of n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine | |
| IL172542A0 (en) | 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide | |
| IL158770A0 (en) | N-formyl hydroxylamine compounds as inhibitors of pdf | |
| IL160819A0 (en) | Novel compounds and compositions as cathepsin inhibitors | |
| HK1086835A1 (en) | N-[({'4-substituted piperazine-1-y}sulfonylmethyl)alkyl]-n-hxdroxyformamide compounds as metallopro teinase inhibitors | |
| IL159125A0 (en) | Novel compounds and compositions as cathepsin inhibitors | |
| HRP20030824A2 (en) | Phenyl heterocyclyl ether derivatives as serotoninre-uptake inhibitors | |
| SI1532145T1 (sl) | Pirazolni sestavki, koristni kot inhibitorji GSK-3 | |
| HUP0401641A3 (en) | Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20130623 |